North America Drug-Device Combination Market – Industry Trends and Forecast to 2028

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

North America Drug-Device Combination Market – Industry Trends and Forecast to 2028

  • Healthcare
  • Published Report
  • Oct 2021
  • North America
  • 350 Pages
  • No of Tables: 21
  • No of Figures: 43

North America Drug-Device Combination Market, By Product (Auto-Injector, Microneedle Patch, Digital Pill, Smart Inhaler, Drug Delivery Hydrogels, Drug-Eluting Lens and Others), Application Type (Orthopedic Diseases, Respiratory Diseases, DiabetesOncologyCardiovascular Diseases and Others), End User (Clinics, Hospitals, Home Care Settings, Ambulatory Care Centers and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast To 2028.

North America Drug-Device Combination Market

Market Analysis and Insights: North America Drug-Device Combination Market

Drug-Device combination market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 10.9% in the forecast period of 2021 to 2028 and is expected to reach USD 17,843.53 million by 2028 from USD 8,086.79 million in 2020. Increasing usage of drug-device combination products, growing incidence of COVID-19 are the major drivers which propelled the demand of the market in the forecast period.

The increasing prevalence of chronic disease advancement in technology effectively help the growth of the drug-device combination market. However, the limitations and complications associated with the Drug-Device combination may hamper the future development of medical devices market. The partnerships and collaborations by significant market players act as opportunities for the growth of the global drug-device combination market.

The drug-device combination market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

North America Drug-Device Combination MarketNorth America Drug-Device Combination Market Scope and Market Size

Drug-device combination market is segmented on the basis of product, application, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of product, the drug-device combination market is segmented into auto-injector, microneedle patch, digital pill, smart inhaler, drug delivery hydrogels, drug-eluting lens, and others. Auto-injector is further sub-segmented into wearable auto-injector, hand-held auto-injector. In 2021, auto-injector holds highest share in the drug-device combination market as large number of patient pool suffering from chronic diseases.
  • On the basis of application, the global drug-device combination market is segmented into orthopedic diseases, respiratory diseases, diabetes, oncology, cardiovascular diseases, and others. In 2021, the orthopedic is expected to dominate the drug-device combination market due to the growing number of surgeries. Moreover, an initiative by the government anticipated propelling the further market growth.
  • On the basis of end users, the drug-device combination market is segmented into clinics, hospitals, home care settings, ambulatory care centers, and others. In 2021, the clinics are expected to dominate the drug-device combination market because most patients are suffering from chronic diseases, so they would be seen in the clinics to get proper regular check-ups, treatment and management. Moreover, due to COVID-19, most patients do not prefer to visit hospitals in fear of infection.
  • On the basis of distribution channel, the drug-device combination market is segmented into direct tender, retail sales, and others. In 2021, the direct tender is expected to dominate the drug-device combination market due to having complete control over the sales and revenue process as well as direct interaction with your customers. The segment is growing due to increasing number of hospitals in developed as well as developing  countries.

North America Drug-Device Combination MarketDrug-Device Combination Market Country Level Analysis

The drug-device combination market is analysed, and market size information is provided by product, application type, end user, and distribution channel. The countries covered in the drug-device combination market report are the U.S., Canada, and Mexico.  

North America is expected to dominate the market due to the high adoption of drug-device combination products by the patients in the region. U.S is dominating in the market and leading the growth in the North America market due to increased presence of key market players in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

Increasing Collaborations and Partnerships in Drug-Device Combination Market is Creating New Opportunities for Players in the Drug-Device Combination Market  

Drug-Device combination market also provides you with detailed market analysis for every country growth. Additionally, it provides data regarding collaborations and partnerships among the major market plyers and start-up companies. Moreover, the growing impact of research and development activities on drug-device combination market growth pace. The data is available for historic period 2010 to 2019

Competitive Landscape and   Medical devices Market Share Analysis

Drug-Device combination market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to drug-device combination market.

The major players covered in the report Mediprint, OcuMedic, Medtronic, GlaxoSmithKline Plc, BD, Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.), Bayer AG, Micron Biomedical, Inc., Otsuka America Pharmaceutical, Inc., VAXXAS, Propeller Health, Raphas Co., Ltd., EOFLOW CO., LTD., Insulet Corporation, TheraJect, Zimmer Biomet, Amgen Inc., Eitan Medical among others domestic and North America players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Growing Collaboration, contract and agreement by key players accelerating the market growth.

For instance,

  • In March 2021, Eitan Medical collaborated with Stevanato for bringing wearable injection solutions to market for the simple and efficient subcutaneous administration of large-volume and high viscosity medications that serve the interests of both patients and pharmaceutical companies. This would strengthen leadership and innovation capabilities globally.
  • In April, EOFlow Co., Ltd. US Subsidiary Nephria got License on new "MXene" Nanomaterial from Drexel University. Nephria got exclusive rights and planned to develop wearable dialysis system, otherwise known as the wearable artificial kidney (WAK), starting with this technology transfer. This would accelerate the technologies in the new therapeutic areas and increases the growth of market.
  • In January 2020, Amgen Inc. announced the successful strategic collaboration with BeiGene. It is predicted that this collaboration enhanced the company’s footprints in China oncology market in the coming years.

Partnerships, joint ventures and other strategies by the market player is enhancing the drug-device combination market growth which also provides the benefit for organisation to improve their offering for better consumer experience.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA DRUG-DEVICE COMBINATION MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PATENT ANALYSIS

4.1.1 MANUFACTURING PROCESS OF COMBINATION PRODUCTS

4.1.2 APPROVAL BY AGENCY

4.1.3 PATENT GRANT

4.1.4 PATENT CERTIFICATIONS:

5 PIPELINE ANALYSIS

6 REGULATORY FRAMEWORKS:

6.1 U.S.

6.2 CANADA

7 REGIONAL SUMMARY

7.1 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET

7.1.1 OVERVIEW

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES

8.1.2 GROWING GERIATRIC POPULATION

8.1.3 ESCALATION IN INNOVATION AND TECHNOLOGIES

8.1.4 RISING RATES OF OBESITY

8.2 RESTRAINTS

8.2.1 PRODUCT RECALLS

8.2.2 RISK ASSOCIATED WITH THE COMBINATION PRODUCTS

8.3 OPPORTUNITIES

8.3.1 RISING EXPENDITURE ON HEALTHCARE

8.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS

8.3.3 GROWING SUPPORT BY HEALTHCARE ORGANIZATIONS AND GOVERNMENT BODIES

8.3.4 INCREASE IN R&D ACTIVITIES BY MEDICAL DEVICE COMPANIES

8.4 CHALLENGE

8.4.1 STRICT REGULATORY FRAMEWORK

9 IMPACT OF COVID-19 PANDEMIC ON THE NORTH AMERICA DRUG-DEVICE COMBINATION MARKET

9.1 IMPACT ON PRICE

9.2 IMPACT ON SUPPLY CHAIN

9.3 IMPACT ON DEMAND

9.4 STRATEGIC DECISIONS FOR MANUFACTURERS

9.5 CONCLUSION

10 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET, BY PRODUCT

10.1 OVERVIEW

10.2 AUTO-INJECTOR

10.2.1 WEARABLE AUTO-INJECTOR

10.2.2 HAND HELD AUTO-INJECTOR

10.3 MICRONEEDLE PATCH

10.4 DIGITAL PILL

10.5 SMART INHALER

10.6 DRUG DELIVERY HYDROGELS

10.7 DRUG-ELUTING LENS

10.8 OTHERS

11 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET, BY APPLICATION

11.1 OVERVIEW

11.2 ORTHOPEDIC DISEASES

11.3 RESPIRATORY DISEASES

11.4 DIABETES

11.5 ONCOLOGY

11.6 CARDIOVASCULAR DISEASES

11.7 OTHERS

12 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET, BY END USER

12.1 OVERVIEW

12.2 CLINICS

12.3 HOSPITALS

12.4 HOME CARE SETTINGS

12.5 AMBULATORY CARE CENTERS

12.6 OTHERS

13 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 DIRECT TENDER

13.3 RETAILS SALES

13.4 OTHERS

14 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET, BY COUNTRY

14.1 OVERVIEW

14.2 NORTH AMERICA

14.2.1 U.S.

14.2.2 CANADA

14.2.3 MEXICO

15 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: COMPANY LANDSCAPE

16 SWOT ANALYSIS

17 COMPANY PROFILE

17.1 AMGEN INC.

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 PRODUCT PORTFOLIO

17.1.4 RECENT DEVELOPMENTS

17.2 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 PRODUCT PORTFOLIO

17.2.4 RECENT DEVELOPMENT

17.3 GLAXOSMITHKLINE PLC

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 PRODUCT PORTFOLIO

17.3.4 RECENT DEVELOPMENT

17.4 MEDTRONIC

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 PRODUCT PORTFOLIO

17.4.4 RECENT DEVELOPMENTS

17.5 INSULET CORPORATION

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 PRODUCT PORTFOLIO

17.5.4 RECENT DEVELOPMENT

17.6 BD

17.6.1 COMPANY SNAPSHOT

17.6.2 REVENUE ANALYSIS

17.6.3 PRODUCT PORTFOLIO

17.6.4 RECENT DEVELOPMENTS

17.7 BAYER AG

17.7.1 COMPANY SNAPSHOT

17.7.2 REVENUE ANALYSIS

17.7.3 PRODUCT PORTFOLIO

17.7.4 RECENT DEVELOPMENT

17.8 EITAN MEDICAL

17.8.1 COMPANY SNAPSHOT

17.8.2 PRODUCT PORTFOLIO

17.8.3 RECENT DEVELOPMENTS

17.9 EOFLOW CO., LTD.

17.9.1 COMPANY SNAPSHOT

17.9.2 PRODUCT PORTFOLIO

17.9.3 RECENT DEVELOPMENTS

17.1 MEDIPRINT

17.10.1 COMPANY SNAPSHOT

17.10.2 PRODUCT PORTFOLIO

17.10.3 RECENT DEVELOPMENT

17.11 MICRON BIOMEDICAL, INC.

17.11.1 COMPANY SNAPSHOT

17.11.2 PRODUCT PORTFOLIO

17.11.3 RECENT DEVELOPMENTS

17.12 OCUMEDIC

17.12.1 COMPANY SNAPSHOT

17.12.2 PRODUCT PORTFOLIO

17.12.3 RECENT DEVELOPMENT

17.13 OTSUKA AMERICA PHARMACEUTICAL, INC.

17.13.1 COMPANY SNAPSHOT

17.13.2 REVENUE ANALYSIS

17.13.3 PRODUCT PORTFOLIO

17.13.4 RECENT DEVELOPMENT

17.14 PROPELLER HEALTH

17.14.1 COMPANY SNAPSHOT

17.14.2 REVENUE ANALYSIS

17.14.3 PRODUCT PORTFOLIO

17.14.4 RECENT DEVELOPMENT

17.15 RAPHAS CO., LTD.

17.15.1 COMPANY SNAPSHOT

17.15.2 REVENUE ANALYSIS

17.15.3 PRODUCT PORTFOLIO

17.15.4 RECENT DEVELOPMENT

17.16 SONCEBOZ

17.16.1 COMPANY SNAPSHOT

17.16.2 PRODUCT PORTFOLIO

17.16.3 RECENT DEVELOPMENT

17.17 THERAJECT

17.17.1 COMPANY SNAPSHOT

17.17.2 PRODUCT PORTFOLIO

17.17.3 RECENT DEVELOPMENT

17.18 VAXXAS

17.18.1 COMPANY SNAPSHOT

17.18.2 PRODUCT PORTFOLIO

17.18.3 RECENT DEVELOPMENTS

17.19 ZIMMER BIOMET

17.19.1 COMPANY SNAPSHOT

17.19.2 REVENUE ANALYSIS

17.19.3 PRODUCT PORTFOLIO

17.19.4 RECENT DEVELOPMENT

18 QUESTIONNAIRE

19 RELATED REPORTS

List of Table

TABLE 1 DRUG-DEVICE COMIBINATION MARKET, PIPELINE ANALYSIS

TABLE 2 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 3 NORTH AMERICA AUTO-INJECTOR IN DRUG-DEVICE COMBINATION MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 4 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 5 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 6 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)

TABLE 7 U.S. DRUG-DEVICE COMBINATION MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 8 U.S. AUTO-INJECTOR IN DRUG-DEVICE COMBINATION MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 9 U.S. DRUG-DEVICE COMBINATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 10 U.S. DRUG-DEVICE COMBINATION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 11 U.S. DRUG-DEVICE COMBINATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 12 CANADA DRUG-DEVICE COMBINATION MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 13 CANADA AUTO-INJECTOR IN DRUG-DEVICE COMBINATION MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 14 CANADA DRUG-DEVICE COMBINATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 15 CANADA DRUG-DEVICE COMBINATION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 16 CANADA DRUG-DEVICE COMBINATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 17 MEXICO DRUG-DEVICE COMBINATION MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 18 MEXICO AUTO-INJECTOR IN DRUG-DEVICE COMBINATION MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 19 MEXICO DRUG-DEVICE COMBINATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 20 MEXICO DRUG-DEVICE COMBINATION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 21 MEXICO DRUG-DEVICE COMBINATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

List of Figure

FIGURE 1 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: MULTIVARIATE MODELLING

FIGURE 7 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: PRODUCT TYPE LIFELINE CURVE

FIGURE 8 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 9 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: DBMR MARKET POSITION GRID

FIGURE 10 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 11 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: VENDOR SHARE ANALYSIS

FIGURE 12 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: SEGMENTATION

FIGURE 13 THE INCREASING PREVALENCE OF CHRONIC DISEASES AND RISING GERIATRIC POPULATION ARE EXPECTED TO DRIVE THE NORTH AMERICA DRUG-DEVICE COMBINATION MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 14 THE AUTO-INJECTOR SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA DRUG-DEVICE COMBINATION MARKET IN THE YEAR 2021 & 2028

FIGURE 15 PORTER'S 5 FORCES

FIGURE 16 PESTEL'S MODEL

FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: NORTH AMERICA DRUG-DEVICE COMBINATION MARKET

FIGURE 18 INCIDENCE OF CANCER, WHICH INCREASES WITH AGE

FIGURE 19 AGEING POPULATION IN THE WORLD (IN MILLIONS)

FIGURE 20 NORTH AMERICA AGEING POPULATION (IN MILLION)

FIGURE 21 MEDICAL DEVICE SPENDING VS. NATIONAL HEALTH EXPENDITURES, 2016

FIGURE 22 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: BY PRODUCT, 2020

FIGURE 23 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: BY PRODUCT, 2019-2028 (USD MILLION)

FIGURE 24 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: BY PRODUCT, CAGR (2021-2028)

FIGURE 25 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 26 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: BY APPLICATION, 2020

FIGURE 27 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: BY APPLICATION, 2019-2028 (USD MILLION)

FIGURE 28 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: BY APPLICATION, CAGR (2021-2028)

FIGURE 29 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 30 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: BY END USER, 2020

FIGURE 31 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 32 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: BY END USER, CAGR (2021-2028)

FIGURE 33 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: BY END USER, LIFELINE CURVE

FIGURE 34 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 35 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 36 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 37 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: SNAPSHOT (2020)

FIGURE 39 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: BY COUNTRY (2020)

FIGURE 40 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: BY COUNTRY (2021 & 2028)

FIGURE 41 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: BY COUNTRY (2020 & 2028)

FIGURE 42 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: BY PRODUCT (2021-2028)

FIGURE 43 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET: COMPANY SHARE 2020 (%)

View Detailed Information Right Arrow

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.